5-Iodo-2-aminoindane (5-IAI) is an entactogen drug of the 2-aminoindane group. [2] . Human anecdotal reports suggest that it is entactogenic but produces little euphoria or stimulation. [2] The drug acts as a releasing agent of serotonin, norepinephrine, and dopamine. [2][3] It produces much less serotonergic neurotoxicity than MDMA in animals. [2]

2013年3月27日 · In 2011, this compound, a psychoactive derivative of 2-aminoindane, was identified in recreational products sold in the United Kingdom. 5-IAI is a rigid analogue of p-iodoamphetamine producing MDMA-like effects. The aim of this paper is to summarize the clinical, pharmacological, and toxicological information about this new potential drug of abuse.

5-Iodo-2-aminoindan | C9H10IN | CID 131506 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.

2010年8月13日 · 5-IAI (5-Iodo-2-aminoindane) is a rigid analogue of amphetamine that has been demonstrated to behaviorally substitute for MDMA, and acts as a monoamine releasing agent. The compound has been suggested to present similar serotonergic neurotoxicity, though considerably lower in severity, to MDMA.

5-Iodo-2-aminoindane (5-IAI) is an entactogen drug of the 2-aminoindane group. Human anecdotal reports suggest that it is entactogenic but produces little euphoria or stimulation. Quick Facts Clinical data, Other names ... The drug acts as a releasing agent of serotonin, norepinephrine, and dopamine.

2014年3月15日 · We characterized the pharmacology of the aminoindanes 5,6-methylenedioxy-2-aminoindane (MDAI), 5-iodoaminoindane (5-IAI), and 2-aminoindane (2-AI), the piperazines meta-chlorophenylpiperazine (m-CPP), trifluoromethylphenylpiperazine (TFMPP), and 1-benzylpiperazine (BZP), and the pipradrol derivatives desoxypipradrol (2 …

5-IAI is a psychoactive analog of p-iodoamphetamine and is indistinguishable, in its physiological effects, from 3,4-methylenedioxymethamphetamine in rats. 1 A single 40 mg/kg dose of 5-IAI significantly reduces both serotonin uptake sites and hippocampal serotonin levels in rats. 2 This product is intended for forensic applications.

Aliases: 5iai. A monoamine triple releaser first synthesised by David Nichols, possesses similar properties to MDMA. Probably neurotoxic in humans, however the extent of this is unclear.

ABSTRACT: The synthesis, analysis, and characterization of 4- and 5-iodo-2-aminoindan (commonly referred to as “4-IAI” and “5-IAI”) are discussed. Analytical data (mass spectrometry, nuclear magnetic resonance spectroscopy, and infrared …

A rigid analogue, 5-iodo-2-aminoindan (5-IAI), of the serotonin neurotoxic halogenated amphetamine p-iodoamphetamine (PIA) was pharmacologically evaluated for production of serotonin neurotoxicity.